首页> 外文OA文献 >A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

【2h】

A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

机译：Neoadjuvant化疗后Her2阴性病理残留侵入性乳腺癌患者TEGAFUR-Uracil辅助化疗的II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
SATORU TANAKA; MITSUHIKO IWAMOTO; KOSEI KIMURA; YUKO TAKAHASHI; HIYOYA FUJIOKA; NAYUKO SATO; RISA TERASAWA; KANAKO KAWAGUCHI; AYANA IKARI; TOMO TOMINAGA; SAKI MAEZAWA; NODOKA UMEZAKI; JUNNA MATSUDA; KAZUHISA UCHIYAMA;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy [J] . Tanaka Satoru, Iwamoto Mitsuhiko, Kimura Kosei, Anticancer Research: International Journal of Cancer Research and Treatment . 2016,第12期

机译：替加氟尿嘧啶辅助化疗对乳腺癌新辅助化疗后HER2阴性病理残留浸润性乳腺癌患者的辅助化疗II期研究
3. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study [J] . Tomoshi Tsuchiya, Ryotaro Kamohara, Masashi Muraoka, BMC Cancer . 2020,第1期

机译：单臂，第2期与口服TEGAFUR-URACIL进行病理淋巴血管侵袭阳性IA非小细胞肺癌的辅助化疗研究：LOGIK0602研究
4. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) [J] . von Minckwitz G., Rezai M., Tesch H., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：唑来膦酸盐用于蒽环类抗生素-紫杉烷类化学疗法治疗早期乳腺癌后的浸润性残留疾病患者-III期新辅助药物附加试验（NaTaN）研究（GBG 36 / ABCSG 29）
5. Usefulness of Adjunction of Digital Breast Tomosynthesis (DBT) to Full-Field Digital Mammography (FFDM) in Evaluation of Pathological Response after Neoadjuvant Chemotherapy (NAC) for Breast Cancer [C] . Nachiko Uchiyama, Takayuki Kinoshita, Takashi Hojo, Breast imaging . 2012

机译：全数字化乳腺X线摄影术（FFDM）与数字乳腺断层合成（DBT）的结合在评估乳腺癌新辅助化疗（NAC）后的病理反应中的作用
6. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
7. A single-arm phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study [O] . Tomoshi Tsuchiya, Ryotaro Kamohara, Masashi Muraoka, 2020

机译：单臂第2期与口服TEGAFUR-URACIL进行病理淋巴血管侵袭阳性IA非小细胞肺癌的辅助化疗研究：LOGIK0602研究
8. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 [O] . S. Sadahiro, T. Tsuchiya, K. Sasaki, 2015

机译：口服尿嘧啶和TEGAFUR的治疗持续时间的随机期III试验作为阶段IIB / III结肠癌患者的辅助化学疗法：JFMC33-0502的最终结果

A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅